Surgery Partners Amends Form 4; Director Holdings Clarified
Rhea-AI Filing Summary
Surgery Partners, Inc. (SGRY) filing amends a previously filed Form 4 to correct an inadvertent error about a reported disposition of common stock. The reporting person, Patricia Anne Maryland, identified as a director, had a transaction date listed as 08/11/2025. The amended record shows a sale code was previously reported in error and clarifies that the number of shares beneficially owned following the reported transaction is 24,583 held directly. The amendment was signed by an attorney-in-fact on 08/13/2025. No exercise or derivative transactions are reported and no price or proceeds are recorded in this amendment.
Positive
- Amendment corrects prior error, improving disclosure accuracy under Section 16
- Clarifies direct ownership of 24,583 common shares, providing clear insider holdings
- No derivatives reported, simplifying assessment of economic exposure
Negative
- Original Form 4 contained an inadvertent error reporting a disposition, indicating a lapse in initial disclosure accuracy
Insights
TL;DR: Amendment corrects a previously reported sale; holdings clarified at 24,583 shares, not a material change to capital structure.
The amendment addresses a reporting error rather than a substantive transfer of economic exposure. The document shows a previously reported disposition code that has been corrected and confirms the reporting person currently holds 24,583 shares directly. There are no derivative instruments disclosed and no transaction proceeds or prices recorded in the amended Form 4, so this filing does not reflect a market-impacting insider sale or acquisition.
TL;DR: Correcting disclosure improves governance transparency; the underlying ownership position is unchanged at 24,583 shares.
The amendment demonstrates adherence to Section 16 reporting obligations by correcting an inadvertent misstatement. While the correction itself is procedural, timely amendment and attorney-in-fact signature indicate remediation of controls around insider reporting. The filing does not reveal any new transfers or derivative positions that would materially affect assessments of insider alignment with shareholders.